ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2975

Journal of Clinical & Experimental Pathology received 2975 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

Vactosertib, ALK5 inhibitor combinatorial treatment with radiation inhibits lung metastasis in syngeneic breast mouse models

Joint Event on 6th World Congress and Expo on Breast Pathology and Cancer Diagnosis & 20th International Conference on Medicinal Chemistry and Rational Drugs

Yhun Y Sheen

Ewha Womans University, Korea

Posters & Accepted Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681-C3-052

Abstract
Radio-resistance and relapse after chemotherapy is a life-threatening problem for breast cancer patients. We identified the molecular signatures of the recurrent breast cancer patients after radiotherapy, which showed the up-regulation of TGF-�² signaling and the epithelial-to-mesenchymal transition (EMT). In order to find the potential therapeutic strategies to improve radiation therapy, we conducted gene set enrichment analysis, a computational method that determines whether an a priori defined gene set shows statistically significant between two phenotypes, using the breast cancer clinical data with Servant cohort (GSE30682). Since we have proved that EW-7197 showed the inhibitory effect in vivo in various breast cancer mouse models previously, we carried out experiments that might test if combinatorial treatment of EW-7197 improves radiation therapy using two syngeneic mouse models. Met 1 cell, which are derived from primary tumors of the FVB/N transgenic mouse with mammary tumor-polyoma virus middle T antigen (MMTV-PyVmt), were injected to fourth inguinal fat pads of FVB/N mice. 4T1 cells, which are derived from primary tumors of Balb/c mice, were injected as same way into Balb/c mice. Mice were treated with the fractionated-radiation (total dose 12 Gy, 4 Gy X3) with or without the combinatorial treatment of EW-7197 (2.5 mg/kg). Conclusion & Significance: Vactosertib (EW-7197), ALK5 inhibitor combinatorial treatment with radiation inhibits tumor growth and metastasis in syngeneic breast mouse models. This effect of Vactosertib (EW-7197), ALK5 inhibitor combinatorial treatment with radiation inhibits tumor growth and metastasis in syngeneic breast mouse models. Vactosertib (EW-7197) maybe related to the breast cancer stem-like phenotype, which is increased by 4Gy irradiation in vitro. We need to further study to conclude the therapeutic mechanisms of EW-7197 on improving radiation therapy. This work was supported by the National Research Foundation of Korea grant funded by the Korea government (NRF-2015M2A2A7A01041499) and (NRF- 2014R1A1A2005644).
Biography

Yhun Sheen has her research interest in developing new anti-cancer drug. She had participated in the development of TEW-7197 which is currently under clinical trial in USA (NCT02160106).

E-mail: yysheen@ewha.ac.kr

Top